Skip to main content

Table 1 Demographic and clinical characteristics of BU+HIV+ co-infected patients

From: Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana

Parameters Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9
Sex Male Male Male Male Female Female Female Female Female
Age (years) 43 42 45 48 50 38 27 40 18
Lesion form Ulcer Ulcer Ulcer Ulcer Ulcer Ulcer Ulcer Nodule Ulcer
Number of lesions 1 2 1 1 1 1 1 1 1
Category of lesion(s) II III II I II II I I II
Lesion site Upper limb Lower limb Lower limb Lower limb Back Lower limb Lower limb Lower limb Upper limb
Lesion healing week 16 52 LF 12 36 20 12 4 4
Occurrence of Paradoxical reaction (PR) No No No PR No PR No PR Yes (at week16) No PR No PR No PR
Type of PR NA NA NA NA NA EWP NA NA NA
HIV load (copies/mL)
Baseline 224,856 134 I 255,950 17,538 76,448 ND ND ND
After BU treatment 1988 LF LF 1,318,694 140 25,272 60 2,576,972 13,227
CD4 count
Baseline          
After BU treatment 130.02     750.3 815.04 753.532 80.6  
Haemoglobin (g/dL)
Baseline 11.7 11 10.3 10.3 9.8 9.8 11.8 8.7 9.7
After treatment 12.5 LF LF 9.3 9.8 9.1 10.7 5.61 ND
Weight (Kg)
Baseline 63 56 50 42 45 66 44 49 52
After treatment 62 60 55 44 49 67 46 43 60
Hepatitis B virus +
Hepatitis C virus +
Buruli ulcer regimen RS CR RS RS RS CR RS RS RS
HIV treatment 3TC, d4T, EFV not known not known not known 3TC, TDF, NVP 3TC, TDF, NVP AZT, 3TC, NVP AZT, 3TC, EFV Not known
Patient on ART before initiation of BU treatment No NA NA NA No Yes No Yes NA
  1. Abbreviations: − Negative, + Positive, RS Rifampicin and Streptomycin, CR Rifampicin and Clarithromycin, LF Lost to follow-up, I Invalid result, ND Not done, d4T Stavudine, 3TC Lamivudine, NVP Nevirapine, TDF Tenofovir, AZT Zidovudine, EFV Efavirenz, PR Paradoxical reaction, NA Not applicable, EWP Enlarged, warm to touch lesion